Abstract
Dimensional approaches to psychopathology interrogate the core neurocognitive domains interacting at the individual level to shape diagnostic symptoms. Embedding this approach in prospective longitudinal studies could transform our understanding of the mechanisms underlying neurodevelopmental disorders. Such designs require us to move beyond traditional group comparisons and determine which domain-specific atypicalities apply at the level of the individual, and whether they vary across distinct phenotypic subgroups. As a proof of principle, this study examines how the domain of face processing contributes to a clinical diagnosis of Autism Spectrum Disorder (ASD). We used an event-related potentials (ERPs) task in a cohort of 8-month-old infants with (n=148) and without (n=68) an older sibling with ASD, and combined traditional case-control comparisons with machine-learning techniques like supervised classification for prediction of clinical outcome at 36 months and Bayesian hierarchical clustering for stratification into subgroups. Our findings converge to indicate that a broad profile of alterations in the time-course of neural processing of faces is an early predictor of later ASD diagnosis. Furthermore, we identified two brain response-defined subgroups in ASD that showed distinct alterations in different aspects of face processing compared to siblings without ASD diagnosis, suggesting that individual differences between infants contribute to the diffuse pattern of alterations predictive of ASD in the first year of life. This study shows that moving from group-level comparisons to pattern recognition and stratification can help to understand and reduce heterogeneity in clinical cohorts, and improve our understanding of the mechanisms that lead to later neurodevelopmental outcomes.
General Scientific Summary This study suggests that neural processing of faces is diffusely atypical in Autism Spectrum Disorder, and that it represents a strong candidate predictor of outcome at an individual level in the first year of life.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by MRC Programme Grant no. G0701484 and MR/K021389/1, the BASIS funding consortium led by Autistica (www.basisnetwork.org), EU-AIMS (the Innovative Medicines Initiative joint undertaking grant agreement no. 115300, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution), and AIMS-2-TRIALS (the Innovative Medicines Initiative 2 joint undertaking grant agreement no. 777394). Charlotte Tye is supported by a Tuberous Sclerosis Association fellowship and the NIHR Maudsley Biomedical Research Centre (BRC) at the Institute of Psychiatry, Psychology & Neuroscience and South London and Maudsley NHS Foundation Trust. Giorgia Bussu has received funding from the Marie Sklodowska Curie Actions of the European Community’s Horizon 2020 Program under grant agreement n°642996 (Brainview).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author Note Charlotte Tye, PhD, Department of Child & Adolescent Psychiatry and MRC Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London; Giorgia Bussu, Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center; Teodora Gliga, Centre for Brain and Cognitive Development, Birkbeck College, University of London; Mayada Elsabbagh, Department of Psychiatry, McGill University; Greg Pasco, Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King’s College London; Kristinn Johnsen, Mentis Cura, Reykjavík, Iceland; Tony Charman, Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King’s College London; South London and Maudsley NHS Foundation Trust (SLaM); Emily J. H. Jones, Centre for Brain and Cognitive Development, Birkbeck College, University of London; Jan K. Buitelaar, Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center; Karakter Child and Adolescent Psychiatry University Centre; Mark H. Johnson, Centre for Brain and Cognitive Development, Birkbeck College, University of London; Department of Psychology, University of Cambridge; the BASIS team is listed in alphabetical order as follows: Anna Blasi, Simon Baron-Cohen, Rachael Bedford, Patrick Bolton, Susie Chandler, Celeste Cheung, Kim Davies, Janice Fernandes, Isobel Gammer, Holly Garwood, Jeanne Giraud, Anna Gui, Kristelle Hudry, Michelle Lieu, Evelyne Mercure, Sarah Lloyd-Fox, Helen Maris, Louise O’Hara, Andrew Pickles, Helena Ribeiro, Erica Salomone, Leslie Tucker, Agnes Volein.
This study complies with APA ethical standards in data treatment. All procedures were in agreement with ethical approval granted by the London Central NREC (approval codes 06/MRE02/73, 08/H0718/76), and one or both parents gave informed consent to participate in the study. The datasets analysed in this study are subject to the BASIS data sharing policy.
Previous studies have reported on partially overlapping datasets (Bedford et al., 2017; Mayada Elsabbagh et al., 2012; Salomone et al., 2018). This study was presented as a poster at the 10th Donders Discussions in Nijmegen, 2017; and as an oral presentation at INSAR in Rotterdam, 2018, and at ETADE Brainview conference in London, 2018.
We wish to thank all the individuals and families who participated in this research. This work was supported by MRC Programme Grant no. G0701484 and MR/K021389/1, the BASIS funding consortium led by Autistica (www.basisnetwork.org), EU-AIMS (the Innovative Medicines Initiative joint undertaking grant agreement no. 115300, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution), and AIMS-2-TRIALS (the Innovative Medicines Initiative 2 joint undertaking grant agreement no. 777394). Charlotte Tye is supported by a Tuberous Sclerosis Association fellowship and the NIHR Maudsley Biomedical Research Centre (BRC) at the Institute of Psychiatry, Psychology & Neuroscience and South London and Maudsley NHS Foundation Trust. Giorgia Bussu has received funding from the Marie Sklodowska Curie Actions of the European Community’s Horizon 2020 Program under grant agreement n°642996 (Brainview). Charlotte Tye and Giorgia Bussu share first authorship of this paper, while Emily Jones, Mark Johnson and Jan Buitelaar share last authorship.
Data Availability
The datasets analysed during the current study are subject to the BASIS data sharing policy (http://www.basisnetwork.org/index.php?option=com_content&task=view&id=41&Itemid=68).
